Biogen Launches First Gene-Targeted ALS Therapy in the Chinese Mainland
Biogen has launched Tofersen, the Chinese mainland’s first gene-targeted therapy for SOD1-ALS, offering hope by slowing motor neuron damage in a disease fatal within 3-5 years.
Tofersen
Read More